Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsUnitedHealthcare FcRn Blockers Prior Auth | OpenPa…
    Ask Trek AI about this page
    ModifiedUnitedHealthcarePolicy CS2026D00111S

    FcRn Blockers

    Customize your policy alerts

    Sign up for UnitedHealthcare Policy CS2026D00111S alerts

    Get alerted when Policy CS2026D00111S changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical benefit coverage for healthcare-professional-administered FcRn blockers used primarily for generalized myasthenia gravis and, for Vyvgart Hytrulo, chronic inflammatory demyelinating polyneuropathy. It applies to UnitedHealthcare Community Plan members except where state-specific Medicaid policies or drug-code policies govern.

    Policy Summary
    PayerUnitedHealthcare
    PolicyFcRn Blockers
    Policy CodePolicy CS2026D00111S
    Change TypeModified
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation of the applicable diagnosis-specific criteria and treatment history.
    SourceLink
    POLICY UPDATE CHANGES

    The generalized myasthenia gravis serologic criterion was revised from requiring a positive anti-AChR antibody test to allowing positive anti-AChR, positive anti-MuSK, positive anti-LRP4, or triple-seronegative results.

    For patients who are anti-AChR antibody positive, anti-LRP4 antibody positive, or triple seronegative, the treatment-failure pathway was revised to require either failure of at least two immunosuppressive agents over at least 12 months or failure of at least one immunosuppressive therapy plus four or more courses of plasmapheresis/plasma exchange and/or immune globulin over at least 12 months without symptom control.

    A separate criterion was added for anti-MuSK antibody-positive patients requiring failure of at least one immunosuppressive agent over at least 12 months.

    ICD-10 diagnosis code G70.0 was added to the applicable codes.

    4FcRn blocker products addressed

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 months
    Maximum authorization period
    ≥5Baseline MG-ADL requirement
    ≥2 pointsContinuation response
    63 daysRystiggo cycle interval
    G70.0ICD-10 code added

    Coverage Criteria

    Imaavy — Initial Therapy

    Imaavy is covered for gMG when ALL of the following initial-therapy requirements are met:

    ALL of the following

    • Submission of medical records confirming that the patient has not failed a previous course of Imaavy therapy.
    • Diagnosis of generalized myasthenia gravis (gMG).
    • ONE of the following

      • Positive serologic test for anti-AChR antibodies.
      • Positive serologic test for anti-MuSK antibodies.
    • Myasthenia Gravis Foundation of America (MGFA) Clinical Classification of class II, III, or IV at initiation of therapy.
    • MG-ADL total score ≥ 5 at initiation of therapy.
    • ONE of the following treatment-history pathways

      • If anti-AChR antibody positive

        • History of failure of at least two immunosuppressive agents over at least 12 months (e.g., azathioprine, corticosteroids, cyclosporine, methotrexate, or mycophenolate).
        • History of failure of at least one immunosuppressive therapy and at least four courses of plasmapheresis/plasma exchanges and/or immune globulin over at least 12 months without symptom control.
      • If anti-MuSK antibody positive: history of failure of at least one immunosuppressive agent over at least 12 months (e.g., azathioprine, corticosteroids, cyclosporine, methotrexate, or mycophenolate).
    • Patient is not receiving Imaavy in combination with a CD19-directed cytolytic antibody (e.g., Uplizna), complement inhibitor (e.g., eculizumab, Ultomiris, or Zilbrysq), another FcRn blocker (e.g., Rystiggo, Vyvgart, or Vyvgart Hytrulo), or immune globulin (e.g., Hizentra, Privigen, or Gammagard).
    • Imaavy is dosed according to FDA-labeled dosing for gMG.
    • Prescribed by, or in consultation with, a neurologist.
    • Initial authorization is for no more than 12 months.

    Imaavy — Continuation Therapy

    Imaavy is covered for continuation therapy when ALL of the following requirements are met:

    ALL of the following

    • Patient has previously been treated with Imaavy.
    • Submission of medical records demonstrating improvement and/or maintenance of at least a 2-point improvement (reduction in score) in MG-ADL from pre-treatment baseline.
    • Reduction in signs and symptoms of myasthenia gravis.
    • Maintenance, reduction, or discontinuation of baseline immunosuppressive therapy (IST) doses used before Imaavy.
    • Patient is not receiving Imaavy in combination with a CD19-directed cytolytic antibody (e.g., Uplizna), complement inhibitor (e.g., eculizumab, Ultomiris, or Zilbrysq), another FcRn blocker (e.g., Rystiggo, Vyvgart, or Vyvgart Hytrulo), or immune globulin (e.g., Hizentra, Privigen, or Gammagard).

    Rystiggo — Initial Therapy

    Rystiggo is covered for gMG initial therapy when ALL of the following requirements are met:

    ALL of the following

    • Submission of medical records confirming that the patient has not failed a previous course of Rystiggo therapy.
    • Diagnosis of generalized myasthenia gravis (gMG).
    • ONE of the following

      • Positive serologic test for anti-AChR antibodies.
      • Positive serologic test for anti-MuSK antibodies.
    • MGFA Clinical Classification of class II, III, or IV at initiation of therapy.

    Rystiggo — Continuation Therapy

    Rystiggo is covered for continuation therapy when ALL of the following requirements are met:

    ALL of the following

    • Patient has previously been treated with Rystiggo.
    • Submission of medical records demonstrating improvement and/or maintenance of at least a 2-point improvement (reduction in score) in MG-ADL from pre-treatment baseline.
    • Reduction in signs and symptoms of myasthenia gravis.
    • Maintenance, reduction, or discontinuation of baseline IST doses used before Rystiggo.
    • Patient is not receiving Rystiggo in combination with a CD19-directed cytolytic antibody (e.g., Uplizna), complement inhibitor (e.g., eculizumab, Ultomiris, or Zilbrysq), another FcRn blocker (e.g., Imaavy, Vyvgart, or Vyvgart Hytrulo), or immune globulin (e.g., Hizentra, Privigen, or Gammagard).

    Vyvgart or Vyvgart Hytrulo — Initial gMG Therapy

    Vyvgart or Vyvgart Hytrulo is covered for gMG initial therapy when ALL of the following requirements are met:

    ALL of the following

    • Submission of medical records confirming that the patient has not failed a previous course of Vyvgart therapy and has not failed a previous course of Vyvgart Hytrulo therapy.
    • Diagnosis of generalized myasthenia gravis (gMG).
    • ONE of the following serologic findings

      • Positive serologic test for anti-AChR antibodies.
      • Positive serologic test for anti-MuSK antibodies.
      • Positive serologic test for anti-LRP4 antibodies.

    Vyvgart or Vyvgart Hytrulo — Initial gMG Treatment Requirements

    The initial gMG request must also meet ALL applicable treatment-history requirements:

    ALL of the following

    • ONE of the following treatment-history pathways

      • If anti-AChR, anti-LRP4, or triple seronegative

        • History of failure of at least two immunosuppressive agents over at least 12 months (e.g., azathioprine, corticosteroids, cyclosporine, methotrexate, or mycophenolate).
        • History of failure of at least one immunosuppressive therapy and at least four courses of plasmapheresis/plasma exchanges and/or immune globulin over at least 12 months without symptom control.
      • If anti-MuSK antibody positive: history of failure of at least one immunosuppressive agent over at least 12 months (e.g., azathioprine, corticosteroids, cyclosporine, methotrexate, or mycophenolate).

    Vyvgart or Vyvgart Hytrulo — Continuation gMG Therapy

    Vyvgart or Vyvgart Hytrulo is covered for continuation of gMG therapy when ALL of the following requirements are met:

    ALL of the following

    • Patient has previously been treated with Vyvgart or Vyvgart Hytrulo.
    • Submission of medical records demonstrating improvement and/or maintenance of at least a 2-point improvement (reduction in score) in MG-ADL from pre-treatment baseline.
    • Reduction in signs and symptoms of myasthenia gravis.
    • Maintenance, reduction, or discontinuation of baseline IST doses used before starting Vyvgart or Vyvgart Hytrulo.
    • Patient is not receiving Vyvgart or Vyvgart Hytrulo in combination with a CD19-directed cytolytic antibody (e.g., Uplizna), complement inhibitor (e.g., eculizumab, Ultomiris, or Zilbrysq), another FcRn blocker (e.g., Imaavy or Rystiggo), or immune globulin (e.g., Hizentra, Privigen, or Gammagard).

    Vyvgart Hytrulo — Initial CIDP Therapy

    Vyvgart Hytrulo is covered for initial CIDP therapy when ALL of the following requirements are met:

    ALL of the following

    • Patient has not failed a previous course of Vyvgart Hytrulo therapy.
    • Diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP).
    • Progressive symptoms present for at least 2 months.
    • Symptomatic polyradiculoneuropathy indicated by progressive or relapsing motor or sensory impairment of more than one limb.
    • At least ONE electrodiagnostic finding

      • Motor distal latency prolongation in 2 nerves.

    Vyvgart Hytrulo — Initial CIDP Treatment Requirements

    Initial CIDP therapy additionally requires ALL of the following treatment conditions:

    ALL of the following

    • Trial and failure after a trial of at least 2 months, contraindication, or intolerance to corticosteroids.
    • ONE of the following immune-globulin pathways

      • Trial and failure after a trial of at least 3 months to an immune globulin (intravenous or subcutaneous).
      • ALL of the following

        • Intolerance to all immune globulins (intravenous or subcutaneous).
        • Dose has been adjusted or escalated to the maximally allowable and/or tolerated dose.

    Vyvgart Hytrulo — Continuation CIDP Therapy

    Vyvgart Hytrulo is covered for continuation of CIDP therapy when ALL of the following requirements are met:

    ALL of the following

    • Patient has previously been treated with Vyvgart Hytrulo.
    • Documentation of positive clinical response to therapy measured by an objective scale (e.g., Rankin, Modified Rankin, or Medical Research Council [MRC] scale).
    • Patient is not receiving Vyvgart Hytrulo in combination with an immune globulin.
    • Vyvgart Hytrulo is dosed according to FDA-labeled dosing for CIDP.
    • Prescribed by, or in consultation with, a neurologist.

    Vyvgart Hytrulo — All Initial CIDP Conditions

    All required conditions for initial Vyvgart Hytrulo therapy for CIDP must be satisfied:

    ALL of the following

    • CIDP diagnosis is supported by progressive symptoms for at least 2 months and symptomatic polyradiculoneuropathy affecting more than one limb.
    • Electrodiagnostic findings are consistent with EFNS/PNS guidelines for definite CIDP, with at least one qualifying demyelinating parameter.
    • Corticosteroid therapy has failed after at least 2 months, or corticosteroids are contraindicated or not tolerated.
    • An applicable immune-globulin requirement is met: failure after at least 3 months, intolerance with maximally allowable and/or tolerated dose adjustment or escalation, or contraindication to all immune globulins.
    • Vyvgart Hytrulo is not combined with immune globulin and is administered according to FDA-labeled CIDP dosing by or in consultation with a neurologist.

    Vyvgart Hytrulo — All Continuation CIDP Conditions

    All required conditions for continuation Vyvgart Hytrulo therapy for CIDP must be satisfied:

    ALL of the following

    • Patient has previously been treated with Vyvgart Hytrulo.
    • Positive clinical response is documented using an objective scale, such as the Rankin, Modified Rankin, or MRC scale.
    • Vyvgart Hytrulo is not combined with immune globulin.
    • Vyvgart Hytrulo is administered according to FDA-labeled CIDP dosing by or in consultation with a neurologist.
    • Reauthorization is for no more than 12 months.

    CIDP Electrodiagnostic Criteria

    Electrodiagnostic findings must be consistent with EFNS/PNS guidelines for definite CIDP. The following findings support demyelination:

    At least one qualifying finding

    • Abnormal temporal dispersion: >30% duration increase between the proximal and distal negative-peak CMAP (at least 100% in the tibial nerve) in ≥2 nerves.
    • Distal CMAP duration prolongation in ≥1 nerve plus at least one other demyelinating parameter in ≥1 other nerve.
    • Low-frequency filter (LFF) 2 Hz F-wave latency above the applicable threshold: median >8.4 ms, ulnar >9.6 ms, peroneal >8.8 ms, or tibial >9.2 ms.
    • LFF 5 Hz F-wave latency above the applicable threshold: median >8.0 ms, ulnar >8.6 ms, peroneal >8.5 ms, or tibial >8.3 ms.
    • LFF 10 Hz F-wave latency above the applicable threshold: median >7.8 ms, ulnar >8.5 ms, peroneal >8.3 ms, or tibial >8.2 ms.

    Vyvgart Hytrulo prefilled syringes for self-administered subcutaneous injection are obtained under the pharmacy benefit. The vial formulation for healthcare-professional administration is addressed under the medical benefit.

    For gMG, Imaavy, Rystiggo, Vyvgart, and Vyvgart Hytrulo must not be used concurrently with CD19-directed cytolytic antibodies, complement inhibitors, other FcRn blockers, or immune globulin, as specified in the applicable criteria.

    For CIDP, Vyvgart Hytrulo must not be administered in combination with an immune globulin.

    For CIDP, Vyvgart Hytrulo must not be used in combination with immune globulin, including intravenous or subcutaneous immune globulin.

    U.S. Food and Drug Administration (FDA) approval alone is not a basis for coverage. Coverage is determined by the applicable medical-necessity criteria in this policy.

    Codes and Operational Thresholds

    HCPCS CodesHCPCS
    J9256Injection, nipocalimab-aahu, 3 mg
    J9332Injection, efgartigimod alfa-fcab, 2 mg
    J9333Injection, rozanolixizumab-noli, 1 mg
    J9334Injection, efgartigimod alfa, 2 mg and hyaluronidase-qvfc
    Diagnosis CodesICD-10
    G70.0Chronic inflammatory demyelinating polyneuritis Myasthenia gravis
    G70.00Myasthenia gravis without (acute) exacerbation
    G70.01Myasthenia gravis with (acute) exacerbation
    Applicable HCPCS CodesHCPCS
    J9256Injection, nipocalimab-aahu, 3 mg
    J9332Injection, efgartigimod alfa-fcab, 2 mg
    J9333Injection, rozanolixizumab-noli, 1 mg
    J9334Injection, efgartigimod alfa, 2 mg and hyaluronidase-qvfc
    Applicable Diagnosis CodesICD-10
    G70.0Chronic inflammatory demyelinating polyneuritis Myasthenia gravis
    G70.00Myasthenia gravis without (acute) exacerbation
    G70.01Myasthenia gravis with (acute) exacerbation
    Applicable ICD-10 Diagnosis Code AddedICD-10
    G70.0Description not stated in this document window
    MGFA Clinical Classification
    Minimum classificationMGFA Clinical Classification class II, III, or IV
    TimingAt initiation of therapy
    Applies toGeneralized myasthenia gravis treatment with FcRn blockers
    MG-ADL Continuation Response
    Required responseAt least a 2-point improvement, meaning a reduction in MG-ADL score from pre-treatment baseline
    Continuation evidenceReduction in signs and symptoms of myasthenia gravis

    Provider Requirements and Denial Risks

    Prior Authorization

    Medical Benefit Prior Authorization Required

    Submit a medical-benefit prior authorization request for covered FcRn blockers administered by a healthcare professional. Covered products include Imaavy IV, Rystiggo SC, Vyvgart IV, and Vyvgart Hytrulo vial SC; the Vyvgart Hytrulo prefilled syringe is obtained under the pharmacy benefit.

    • Medical-benefit products: Imaavy, Rystiggo, Vyvgart, and Vyvgart Hytrulo vial.
    • Vyvgart Hytrulo prefilled syringe: pharmacy benefit.
    Prior Authorization

    CIDP Authorization and Duration Limits

    Obtain prior authorization for Vyvgart Hytrulo when treating CIDP. Initial and renewal authorizations are limited to no more than 12 months.

    • Applies to CIDP treatment with Vyvgart Hytrulo.
    • Initial authorization: no more than 12 months.
    • Reauthorization: no more than 12 months.

    Policy Scope and Context

    This policy addresses FcRn blockers administered by a healthcare professional for generalized myasthenia gravis, including Imaavy, Rystiggo, Vyvgart, and the Vyvgart Hytrulo vial. Vyvgart Hytrulo is also addressed for adult chronic inflammatory demyelinating polyneuropathy (CIDP) under specified criteria. Coverage requires clinically significant disease, applicable prior-treatment history, appropriate neurologist involvement, FDA-labeled dosing, and documented response for continued treatment. The self-administered Vyvgart Hytrulo prefilled syringe is obtained under the pharmacy benefit rather than this medical benefit policy.

    Clinical Definitions and Scales

    MGFA Clinical Classification
    Qualifying classesClass II, III, or IV
    ClassificationMyasthenia Gravis Foundation of America Clinical Classification
    TimingClassification must apply at initiation of therapy
    MG-ADL
    ScaleMyasthenia Gravis Activities of Daily Living (MG-ADL)
    Initiation thresholdTotal score of at least 5
    TimingAt initiation of therapy

    Initial Therapy Decision Criteria

    Imaavy Initial Therapy – Complete Decision Tree

    Covered when all initial-therapy criteria are met.

    Imaavy initial therapy

    • Clinical eligibility: No previous Imaavy treatment failure; diagnosis of gMG; positive anti-AChR or anti-MuSK serologic test; MGFA class II, III, or IV; and MG-ADL total score ≥5 at initiation.MG-ADL ≥5
    • Prior treatment pathway

      • Anti-AChR-positive pathway

        • Failure of at least two immunosuppressive agents over at least 12 months.≥2 agents; ≥12 months

    Continuation and Reauthorization Criteria

    Imaavy Continuation – Prior Treatment, Response, and Ongoing Therapy

    All continuation requirements must be met.

    Imaavy continuation

    • Previously treated with Imaavy.
    • At least a 2-point MG-ADL reduction from pre-treatment baseline is improved or maintained; signs and symptoms of myasthenia gravis are reduced; and baseline immunosuppressive therapy is maintained, reduced, or discontinued.MG-ADL reduction ≥2 points
    • No prohibited combination therapy; FDA-labeled gMG dosing; neurologist prescribing or consultation; and reauthorization for no more than 12 months.Reauthorization ≤12 months

    Rystiggo Continuation – Response, Combination, Interval, and Authorization

    Required Prior Treatment Pathways

    StepPatient subgroupRequired prior therapyMinimum duration / additional requirement
    1Anti-AChR-positive, anti-LRP4-positive, or triple-seronegative generalized myasthenia gravisFailure of at least two immunosuppressive agentsAt least 12 months
    1Anti-AChR-positive, anti-LRP4-positive, or triple-seronegative generalized myasthenia gravisFailure of at least one immunosuppressive therapy plus four or more courses of plasmapheresis/plasma exchange and/or immune globulin without symptom controlAt least 12 months
    1Anti-MuSK-positive generalized myasthenia gravisFailure of at least one immunosuppressive agentAt least 12 months
    StepTherapy sequenceQualifying requirementDuration / dose requirement
    1CorticosteroidsTrial and failure, or documented contraindication or intoleranceTrial of at least 2 months when used
    1Immune globulin after corticosteroidsTrial and failure; or intolerance to all immune globulins with dose adjustment or escalation to the maximally allowable and/or tolerated dose; or contraindication to all immune globulinsAt least 3 months when trialed
    StepRequired sequenceQualifying pathwayDuration / additional requirement
    1Corticosteroids firstTrial and failure of corticosteroidsAt least 2 months
    1Then immune globulinTrial and failure of intravenous or subcutaneous immune globulinAt least 3 months
    1Then immune globulinIntolerance to all immune globulins, with dose adjustment or escalation to the maximally allowable and/or tolerated doseMaximally allowable and/or tolerated dose
    1Then immune globulinContraindication to all immune globulinsNo trial duration specified

    Administration and Benefit Channel

    Billing Rule

    Administer covered products in the office

    Imaavy and Vyvgart are administered intravenously by a healthcare professional. Rystiggo and the Vyvgart Hytrulo vial are administered subcutaneously by a healthcare professional under the medical benefit.

    • Use the office-based medical benefit route for these healthcare-professional-administered presentations.
    Billing Rule

    Route the prefilled syringe through pharmacy

    The Vyvgart Hytrulo prefilled syringe is self-administered subcutaneously and is obtained under the pharmacy benefit rather than the medical benefit.

    • Do not bill the self-administered prefilled syringe under the medical benefit policy.
    Policy Summary
    PayerUnitedHealthcare
    PolicyFcRn Blockers
    Policy CodePolicy CS2026D00111S
    Change TypeModified
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with documentation of the applicable diagnosis-specific criteria and treatment history.
    SourceLink
    On This Page
    Coverage CriteriaCodes and Operational ThresholdsProvider Requirements and Denial RisksPolicy Scope and ContextClinical Definitions and ScalesInitial Therapy Decision CriteriaContinuation and Reauthorization CriteriaRequired Prior Treatment PathwaysAdministration and Benefit Channel

    Add-on IST, IST dose escalation, or additional rescue therapy from baseline to treat myasthenia gravis or symptom exacerbation while on Imaavy is considered treatment failure.

  1. Imaavy is dosed according to FDA-labeled dosing for gMG.
  2. Prescribed by, or in consultation with, a neurologist.
  3. Reauthorization is for no more than 12 months.
  4. MG-ADL total score ≥ 5 at initiation of therapy.
  5. ONE of the following treatment-history pathways

    • If anti-AChR antibody positive

      • History of failure of at least two immunosuppressive agents over at least 12 months (e.g., azathioprine, corticosteroids, cyclosporine, methotrexate, or mycophenolate).
      • History of failure of at least one immunosuppressive therapy and at least four courses of plasmapheresis/plasma exchanges and/or immune globulin over at least 12 months without symptom control.
    • If anti-MuSK antibody positive: history of failure of at least one immunosuppressive agent over at least 12 months (e.g., azathioprine, corticosteroids, cyclosporine, methotrexate, or mycophenolate).
  6. Add-on IST, IST dose escalation, or additional rescue therapy from baseline to treat myasthenia gravis or symptom exacerbation while on Rystiggo is considered treatment failure.

  7. Rystiggo is not given sooner than 63 days from the start of the previous treatment cycle.
  8. Rystiggo is dosed according to FDA-labeled dosing for gMG.
  9. Prescribed by, or in consultation with, a neurologist.
  10. Reauthorization is for no more than 12 months.
  11. Negative serologic tests for anti-AChR, anti-MuSK, and anti-LRP4 antibodies (triple seronegative).
  12. MGFA Clinical Classification of class II, III, or IV at initiation of therapy.
  13. MG-ADL total score ≥ 5 at initiation of therapy.
  14. Patient is not receiving Vyvgart or Vyvgart Hytrulo in combination with a CD19-directed cytolytic antibody (e.g., Uplizna), complement inhibitor (e.g., eculizumab, Ultomiris, or Zilbrysq), another FcRn blocker (e.g., Imaavy or Rystiggo), or immune globulin (e.g., Hizentra, Privigen, or Gammagard).
  15. Vyvgart or Vyvgart Hytrulo is dosed according to FDA-labeled dosing for gMG.
  16. Prescribed by, or in consultation with, a neurologist.
  17. Initial authorization is for no more than 12 months.
  18. Add-on IST, IST dose escalation, or additional rescue therapy from baseline to treat myasthenia gravis or symptom exacerbation while on Vyvgart or Vyvgart Hytrulo is considered treatment failure.

  19. Reduction of motor conduction velocity in 2 nerves.
  20. Prolongation of F-wave latency in 2 nerves.
  21. Absence of F-waves in at least 1 nerve.
  22. Partial motor conduction block of at least 1 motor nerve.
  23. Abnormal temporal dispersion in at least 2 nerves.
  24. Distal CMAP duration increase in at least 1 nerve.
  25. Contraindication to all immune globulins (intravenous or subcutaneous).
  26. Patient is not receiving Vyvgart Hytrulo in combination with an immune globulin.
  27. Vyvgart Hytrulo is dosed according to FDA-labeled dosing for CIDP.
  28. Prescribed by, or in consultation with, a neurologist.
  29. Initial authorization is for no more than 12 months.
  30. Reauthorization is for no more than 12 months.
  31. LFF 20 Hz F-wave latency above the applicable threshold: median >7.4 ms, ulnar >7.8 ms, peroneal >8.1 ms, or tibial >8.0 ms.
  32. Baseline therapyMaintenance, reduction, or discontinuation of baseline immunosuppressive therapy
    Rystiggo Treatment-Cycle Interval
    Minimum interval63 days
    Interval measured fromThe start of the previous Rystiggo treatment cycle
    Coverage conditionRystiggo must not be administered sooner than this interval
    Immunosuppressive-Agent Treatment History
    Primary pathwayFailure of at least two immunosuppressive agents over at least 12 months
    Alternative pathwayFailure of at least one immunosuppressive therapy plus four or more courses of plasmapheresis, plasma exchange, and/or immune globulin over at least 12 months without symptom control
    Anti-MuSK pathwayFailure of at least one immunosuppressive agent over at least 12 months
    Example agentsAzathioprine, corticosteroids, cyclosporine, methotrexate, or mycophenolate
    CIDP Symptom Duration
    Minimum durationAt least 2 months
    Required clinical patternProgressive symptoms with symptomatic polyradiculoneuropathy
    DistributionProgressive or relapsing motor or sensory impairment affecting more than one limb
    CIDP Corticosteroid Trial
    Minimum trial durationAt least 2 months
    Required outcomeTrial and failure of corticosteroids
    Alternative qualificationsA contraindication or intolerance to corticosteroids also qualifies
    CIDP Immune Globulin Trial
    Minimum trial durationAt least 3 months
    Covered productsIntravenous immunoglobulin or subcutaneous immunoglobulin
    Required outcomeTrial and failure of an immune globulin, unless a qualifying intolerance or contraindication pathway applies
    Corticosteroid Trial
    Minimum durationAt least 2 months
    TherapyCorticosteroids
    Qualifying alternativesContraindication or intolerance to corticosteroids
    Immune Globulin Trial
    Minimum durationAt least 3 months
    TherapyIntravenous or subcutaneous immune globulin
    Alternative pathwaysIntolerance to all immune globulins with maximally allowable or tolerated dose adjustment, or contraindication to all immune globulins
    Initial Authorization
    Authorization typeInitial authorization
    Maximum durationNo more than 12 months
    Applicable treatmentVyvgart Hytrulo for CIDP
    Reauthorization
    Authorization typeReauthorization
    Maximum durationNo more than 12 months
    Applicable treatmentVyvgart Hytrulo for CIDP continuation therapy
    Motor Distal Latency Prolongation
    ThresholdAt least 50% above the upper limit of normal (ULN)
    Nerves requiredTwo nerves
    FindingMotor distal latency prolongation
    Motor Conduction Velocity Reduction
    ThresholdAt least 30% below the lower limit of normal (LLN)
    Nerves requiredTwo nerves
    FindingReduction of motor conduction velocity
    Abnormal Temporal Dispersion
    Duration increaseMore than 30% between the proximal and distal negative peak CMAP
    Nerves requiredAt least 2 nerves
    Tibial nerve thresholdAt least 100% duration increase in the tibial nerve
    CIDP Electrodiagnostic Criteria
    Temporal dispersion pathwayMore than 30% duration increase between proximal and distal negative peak CMAP in at least 2 nerves, with at least 100% in the tibial nerve
    Distal CMAP pathwayDistal CMAP duration prolongation in at least 1 nerve plus at least 1 other demyelinating parameter in at least 1 other nerve
    Additional strongly supportive findingsMotor distal latency prolongation, reduced motor conduction velocity, F-wave abnormalities, absent F-waves, or motor conduction block as specified in the policy
    Weak supportCriteria present in only one nerve are weakly supportive of demyelination
    Low-frequency filter thresholdsThe policy specifies median, ulnar, peroneal, and tibial distal CMAP duration thresholds at 2, 5, 10, and 20 Hz
    Step Therapy

    Document Required gMG Treatment History

    For gMG initial therapy, document the required prior-treatment failure history based on antibody status. AChR-positive, MuSK-positive, and applicable LRP4-positive or triple-seronegative patients have different immunosuppressive and rescue-therapy requirements.

    • AChR-positive, LRP4-positive, or triple-seronegative: failure of at least two immunosuppressive agents over at least 12 months, or failure of at least one immunosuppressive therapy plus at least four courses of plasmapheresis/plasma exchange and/or immune globulin over at least 12 months without symptom control.
    • MuSK-positive: failure of at least one immunosuppressive agent over at least 12 months.
    • Examples include azathioprine, corticosteroids, cyclosporine, methotrexate, and mycophenolate.
    Step Therapy

    CIDP Prerequisite Therapy

    For CIDP initial therapy, document a trial and failure of corticosteroids after at least two months, unless corticosteroids are contraindicated or not tolerated. Also document the required immune-globulin prerequisite pathway.

    • Corticosteroid trial and failure: at least 2 months.
    • If corticosteroids are contraindicated or intolerable, document the applicable exception.

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: step_therapy

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: step_therapy

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: billing_rule

    Unsupported block type: prior_auth

    Unsupported block type: documentation

    Unsupported block type: prior_auth

    Note

    FDA Approval Alone Does Not Establish Coverage

    FDA approval alone does not establish coverage under this policy. Coverage remains subject to the policy criteria, benefit terms, applicable codes, and other governing requirements.

    • FDA indications are informational and do not guarantee reimbursement or claim payment.
    • Submit documentation meeting the applicable medical-necessity and authorization requirements.
    CIDP
    ConditionChronic inflammatory demyelinating polyneuropathy (CIDP)
    Symptom durationProgressive symptoms present for at least 2 months
    Clinical involvementSymptomatic polyradiculoneuropathy with progressive or relapsing motor or sensory impairment of more than one limb
    Diagnostic confirmationElectrodiagnostic findings consistent with EFNS/PNS guidelines for definite CIDP
    MG-ADL Scale
    CompositionEight items assessing the impact of generalized myasthenia gravis on daily functions
    Item scoringEach item is scored from 0 to 3
    Total range0 to 24
    InterpretationHigher scores indicate greater impairment
    QMG Scale
    Composition13-item grading system assessing muscle weakness
    Item scoringEach item is scored from 0 to 3
    Total range0 to 39
    InterpretationHigher scores indicate more severe impairment
    Typical CIDP
    Weakness patternProgressive or relapsing, symmetric proximal and distal weakness of the upper and lower limbs
    Sensory involvementSensory involvement of at least two limbs
    DevelopmentDeveloping over at least 8 weeks
    ReflexesAbsent or reduced tendon reflexes in all limbs
    CIDP Variants
    Recognized variantsDistal, multifocal, focal, motor, and sensory CIDP
    Distal CIDPDistal sensory loss and muscle weakness predominantly in the lower limbs
    Multifocal CIDPUsually asymmetric sensory loss and muscle weakness, upper-limb predominant, in more than one limb
    Focal CIDPSensory loss and muscle weakness in only one limb
    Motor or sensory CIDPMotor symptoms and signs without sensory involvement, or sensory symptoms and signs without motor involvement
    Failure of at least one immunosuppressive therapy plus at least four courses of plasmapheresis/plasma exchange and/or immune globulin over at least 12 months without symptom control.≥1 therapy; ≥4 courses; ≥12 months
  33. Anti-MuSK-positive pathway: Failure of at least one immunosuppressive agent over at least 12 months.≥1 agent; ≥12 months
  34. Administration requirements: No prohibited combination therapy; FDA-labeled gMG dosing; neurologist prescribing or consultation; and initial authorization for no more than 12 months.Authorization ≤12 months
  35. Rystiggo Initial Therapy – Complete Decision Tree

    Covered when all initial-therapy criteria are met.

    Rystiggo initial therapy

    • Clinical eligibility: No previous Rystiggo treatment failure; diagnosis of gMG; positive anti-AChR or anti-MuSK serologic test; MGFA class II, III, or IV; and MG-ADL total score ≥5 at initiation.MG-ADL ≥5
    • Prior treatment pathway

      • Anti-AChR-positive pathway

        • Failure of at least two immunosuppressive agents over at least 12 months.≥2 agents; ≥12 months
        • Failure of at least one immunosuppressive therapy plus at least four courses of plasmapheresis/plasma exchange and/or immune globulin over at least 12 months without symptom control.≥1 therapy; ≥4 courses; ≥12 months
      • Anti-MuSK-positive pathway: Failure of at least one immunosuppressive agent over at least 12 months.≥1 agent; ≥12 months
    • Administration requirements: No prohibited combination therapy; treatment is administered no sooner than 63 days from the previous cycle start; FDA-labeled gMG dosing; neurologist prescribing or consultation; and initial authorization for no more than 12 months.≥63 days; authorization ≤12 months

    Vyvgart or Vyvgart Hytrulo Initial gMG – Complete Decision Tree

    Covered when all initial-therapy criteria are met.

    Vyvgart or Vyvgart Hytrulo initial gMG therapy

    • Clinical eligibility: No previous treatment failure with the applicable product; diagnosis of gMG; positive anti-AChR, anti-MuSK, or anti-LRP4 serologic test, or triple-seronegative status; MGFA class II, III, or IV; and MG-ADL total score ≥5 at initiation.MG-ADL ≥5
    • Prior treatment pathway

      • Anti-AChR-positive, anti-LRP4-positive, or triple-seronegative pathway

        • ANY of the following

          • Failure of at least two immunosuppressive agents over at least 12 months.≥2 agents; ≥12 months
          • Failure of at least one immunosuppressive therapy plus at least four courses of plasmapheresis/plasma exchange and/or immune globulin over at least 12 months without symptom control.≥1 therapy; ≥4 courses; ≥12 months
      • Anti-MuSK-positive pathway: Failure of at least one immunosuppressive agent over at least 12 months.≥1 agent; ≥12 months
    • Administration requirements: No prohibited combination therapy; FDA-labeled gMG dosing; neurologist prescribing or consultation; and initial authorization for no more than 12 months.Authorization ≤12 months

    Vyvgart Hytrulo Initial CIDP – Complete Decision Tree

    Covered when all initial CIDP criteria are met.

    Vyvgart Hytrulo initial CIDP therapy

    • Diagnosis: No previous Vyvgart Hytrulo treatment failure; progressive CIDP symptoms for at least 2 months; symptomatic polyradiculoneuropathy with progressive or relapsing motor or sensory impairment of more than one limb; and qualifying electrodiagnostic findings consistent with definite CIDP.Symptoms ≥2 months
    • Corticosteroid requirement

      • Trial and failure after at least 2 months of corticosteroids.≥2 months
      • Contraindication or intolerance to corticosteroids.
    • Immune globulin requirement

      • Trial and failure after at least 3 months of intravenous or subcutaneous immune globulin.≥3 months
      • Intolerance to all immune globulins with escalation to the maximally allowable and/or tolerated dose.
      • Contraindication to all immune globulins.
    • Treatment and authorization: No concurrent immune globulin; FDA-labeled CIDP dosing; neurologist prescribing or consultation; and initial authorization for no more than 12 months.Authorization ≤12 months

    Vyvgart Hytrulo Initial CIDP Therapy – All Required Criteria

    All of the following CIDP initial criteria must be met.

    Initial CIDP criteria

    • Corticosteroid prerequisite: Trial and failure of corticosteroids after at least 2 months.≥2 months
    • Immune globulin prerequisite

      • Trial and failure of intravenous or subcutaneous immune globulin after at least 3 months.≥3 months
      • Intolerance to all immune globulins with dose adjustment or escalation to the maximally allowable and/or tolerated dose.
      • Contraindication to all immune globulins.
    • Other required conditions: No concurrent immune globulin; FDA-labeled CIDP dosing; neurologist prescribing or consultation; and initial authorization for no more than 12 months.Authorization ≤12 months

    Generalized Myasthenia Gravis Initial Therapy

    The applicable serologic pathway and treatment-failure requirements must be met.

    Revised gMG initial-therapy criteria

    • Permitted serologic results

      • Positive anti-AChR antibody test.
      • Positive anti-MuSK antibody test.
      • Positive anti-LRP4 antibody test.
      • Negative anti-AChR, anti-MuSK, and anti-LRP4 antibody tests (triple seronegative).
    • Treatment-failure pathway

      • Anti-AChR-positive, anti-LRP4-positive, or triple-seronegative pathway

        • ANY of the following

          • Failure of at least two immunosuppressive agents over at least 12 months.≥2 agents; ≥12 months
          • Failure of at least one immunosuppressive therapy plus four or more courses of plasmapheresis/plasma exchange and/or immune globulin over at least 12 months without symptom control.≥1 therapy; ≥4 courses; ≥12 months
      • Anti-MuSK-positive pathway: Failure of at least one immunosuppressive agent over at least 12 months.≥1 agent; ≥12 months

    All continuation requirements must be met.

    Rystiggo continuation

    • Previously treated with Rystiggo.
    • At least a 2-point MG-ADL reduction from pre-treatment baseline is improved or maintained; signs and symptoms of myasthenia gravis are reduced; and baseline immunosuppressive therapy is maintained, reduced, or discontinued.MG-ADL reduction ≥2 points
    • No prohibited combination therapy; treatment cycles begin no sooner than 63 days from the prior cycle start; FDA-labeled gMG dosing; neurologist prescribing or consultation; and reauthorization for no more than 12 months.≥63 days between cycle starts; reauthorization ≤12 months

    Vyvgart or Vyvgart Hytrulo Continuation for gMG

    All continuation requirements must be met.

    Vyvgart or Vyvgart Hytrulo continuation for gMG

    • Previously treated with Vyvgart or Vyvgart Hytrulo.
    • At least a 2-point MG-ADL reduction from pre-treatment baseline is improved or maintained; signs and symptoms of myasthenia gravis are reduced; and baseline immunosuppressive therapy is maintained, reduced, or discontinued.MG-ADL reduction ≥2 points
    • No prohibited combination therapy; FDA-labeled gMG dosing; neurologist prescribing or consultation; and reauthorization for no more than 12 months.Reauthorization ≤12 months

    Vyvgart Hytrulo Continuation for CIDP – Decision Tree

    All continuation requirements must be met.

    Vyvgart Hytrulo continuation for CIDP

    • Previously treated with Vyvgart Hytrulo.
    • Positive clinical response is documented using an objective scale, such as the Rankin, Modified Rankin, or Medical Research Council scale.
    • No concurrent immune globulin; FDA-labeled CIDP dosing; neurologist prescribing or consultation; and reauthorization for no more than 12 months.Reauthorization ≤12 months

    Vyvgart Hytrulo Continuation – All CIDP Criteria

    All CIDP continuation criteria must be met.

    Continuation requirements

    • The patient has previously been treated with Vyvgart Hytrulo.
    • A positive clinical response is documented using an objective scale, such as the Rankin, Modified Rankin, or Medical Research Council scale.
    • The patient is not receiving Vyvgart Hytrulo in combination with an immune globulin.
    • Vyvgart Hytrulo is dosed according to FDA-labeled CIDP dosing.
    • Vyvgart Hytrulo is prescribed by or in consultation with a neurologist.
    • Reauthorization is for no more than 12 months.≤12 months